^
Association details:
| Biomarker: | HER-2 underexpression + CCNE1 amplification |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) + adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Published date:
06/06/2023
Excerpt:
In vivo, the T-DXd + adavosertib combination significantly increased γH2AX and antitumor activity in HER2 low, cyclin E amplified gastroesophageal cancer PDX models and prolonged event-free survival (EFS) in a HER2 overexpressing gastroesophageal cancer model...We provide rationale for combining T-DXd with adavosertib in HER2-expressing cancers, especially with co-occuring CCNE1 amplifications.
DOI:
10.1158/1078-0432.CCR-23-0103
Source:
Title:
327/2-Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers
Published date:
03/09/2022
Excerpt:
T-DXd induced durable tumor regression in two HER2 amplified and HER2 overexpressing gastroesophageal PDX cancer models with HER2 amplification/3+ overexpression and concomitant cyclin E amplification/expression. Adavosertib enhanced the antitumor activity of T-DXd in two HER2 low, cyclin E amplified gastroesophageal cancer PDX models (one with an ERBB2 G778A mutation).
